22.728 articles found

Screening and Treatment Methods Using IGS5 Enzymes of the Metalloprotease Family

DELEERSNIJDER WILLY, KARIMI-NEJAD YASMIN, WESKE MICHAEL, ZIEGLER DIETER.

· 2011-05-25

Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France.

Fayard C, Bonaventure A, Benatru I, Roze E, Dumurgier J, Moisan F, Soumaré A, Houssinot J, Dupupet JL, Mazurie JL, Balaboi I, Houeto JL, Krim E, Ranoux D, Goldberg M, Imbernon E, Moreau T, Giroud M, Tzourio C, Elbaz A.

Parkinsonism Relat Disord · 2011-05-25

DOI: 10.1016/j.parkreldis.2011.04.020PMID: 21612970

Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.

Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.

J Clin Pharmacol · 2011-05-24

DOI: 10.1177/0091270011409232PMID: 21610205

PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE NEUROLOGICAL BRAIN DISORDERS

SUH YOO-HUN, KOPPULA SUSHRUTA, NOH SU-JIN.

· 2011-05-18

Impulse control disorders and dopaminergic treatments in Parkinson's disease.

Villa C, Pascual-Sedano B, Pagonabarraga J, Kulisevsky J.

Rev Neurol (Paris) · 2011-05-18

DOI: 10.1016/j.neurol.2011.01.018PMID: 21596410

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.

Antonini A, Calandrella D.

Neuropsychiatr Dis Treat · 2011-05-15

DOI: 10.2147/ndt.s10097PMID: 21654875

A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.

Iansek R, Danoudis M.

Parkinsonism Relat Disord · 2011-05-14

DOI: 10.1016/j.parkreldis.2011.04.012PMID: 21576031

[Levodopa-responsive parkinsonism-dystonia due to a traumatic injury of the substantia nigra].

Pérez Errazquin F, Gomez Heredia MJ.

Neurologia · 2011-05-13

DOI: 10.1016/j.nrl.2011.03.011PMID: 21570743

Improvement in drug-induced parkinsonism with electroconvulsive therapy.

Baez MA, Avery J.

Am J Geriatr Pharmacother · 2011-05-12

DOI: 10.1016/j.amjopharm.2011.04.005PMID: 21565562

Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Gogoi S, Antonio T, Rajagopalan S, Reith M, Andersen J, Dutta AK.

ChemMedChem · 2011-05-12

DOI: 10.1002/cmdc.201100140PMID: 21567969

Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?

Teodoro T, Pires D, Rosa MM, Coelho M, Sampaio C, Ferreira JJ.

Mov Disord · 2011-05-12

DOI: 10.1002/mds.23760PMID: 21567458

Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.

Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry · 2011-05-12

DOI: 10.1016/j.pnpbp.2011.05.003PMID: 21605615